Slavia Chankova
Showing 1–2 of 2 transcripts.
- The Economist24 min
Covid-19: why vaccine mistrust is growing
Professor Jonathan Heaney, Professor Heidi Larson, Dr Jonathan Kennedy, Kristin Urquiza, Neil Johnson, Fadi Kouran, Slavia Chankova
With over 20 COVID-19 vaccine candidates in development, experts warn that failing to achieve 70% population uptake due to widespread hesitancy could necessitate indefinite social restrictions. This crisis of trust is driven by political polarization, the legacy of the retracted Andrew Wakefield study, and algorithmic amplification of misinformation on social media platforms that have disproportionately spread falsehoods from figures like President Trump. In response, health organizations and tech-savvy clinics are launching counter-misinformation campaigns to protect herd immunity goals against hostile narratives that link political populism with declining public confidence.
- The Economist11 min
Covid-19: When will a vaccine be ready?
Slavia Chankova, Callum Williams
Global teams are racing to develop vaccines with an estimated 80% success probability, yet full worldwide distribution is projected to take at least two years due to significant manufacturing constraints. While the pandemic causes weekly economic losses of $200 billion to $250 billion, achieving herd immunity requires overcoming distribution inequities and public skepticism, with experts recommending that wealthy nations support GAVI to ensure access for developing countries. Industry and government leaders face a complex balancing act between incentivizing rapid innovation through potential profits and adhering to ethical protocols that prioritize healthcare workers, the elderly, and vulnerable populations.